Elevation Oncology Statistics

Total Valuation

IntoCell has a market cap or net worth of KRW 362.28 billion. The enterprise value is 361.82 billion.

Market Cap	362.28B
Enterprise Value	361.82B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

IntoCell has 14.85 million shares outstanding. The number of shares has increased by 1.47% in one year.

Current Share Class	14.85M
Shares Outstanding	14.85M
Shares Change (YoY)	+1.47%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	22.63%
Owned by Institutions (%)	9.56%
Float	11.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	122.91
PB Ratio	92.62
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-40.43
EV / Sales	122.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-49.62

Financial Position

The company has a current ratio of 0.80, with a Debt / Equity ratio of 2.58.

Current Ratio	0.80
Quick Ratio	0.80
Debt / Equity	2.58
Debt / EBITDA	n/a
Debt / FCF	-1.38
Interest Coverage	-29.84

Financial Efficiency

Return on equity (ROE) is -104.44% and return on invested capital (ROIC) is -29.62%.

Return on Equity (ROE)	-104.44%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-29.62%
Return on Capital Employed (ROCE)	-125.41%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	34,667.00
200-Day Moving Average	n/a
Relative Strength Index (RSI)	39.56
Average Volume (20 Days)	410,509

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, IntoCell had revenue of KRW 2.95 billion and -8.95 billion in losses. Loss per share was -679.25.

Revenue	2.95B
Gross Profit	2.93B
Operating Income	-8.83B
Pretax Income	-8.95B
Net Income	-8.95B
EBITDA	-8.16B
EBIT	-8.83B
Loss Per Share	-679.25

Full Income Statement

Balance Sheet

The company has 10.55 billion in cash and 10.09 billion in debt, giving a net cash position of 460.82 million or 31.04 per share.

Cash & Cash Equivalents	10.55B
Total Debt	10.09B
Net Cash	460.82M
Net Cash Per Share	31.04
Equity (Book Value)	3.91B
Book Value Per Share	294.84
Working Capital	-3.04B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.20 billion and capital expenditures -90.92 million, giving a free cash flow of -7.29 billion.

Operating Cash Flow	-7.20B
Capital Expenditures	-90.92M
Free Cash Flow	-7.29B
FCF Per Share	-491.07

Full Cash Flow Statement

Margins

Gross Margin	99.41%
Operating Margin	-299.44%
Pretax Margin	-303.64%
Profit Margin	n/a
EBITDA Margin	-276.79%
EBIT Margin	-299.44%
FCF Margin	n/a

Dividends & Yields

IntoCell does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.47%
Shareholder Yield	n/a
Earnings Yield	-2.47%
FCF Yield	-2.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

IntoCell has an Altman Z-Score of -6.55 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.55
Piotroski F-Score	1